Business Context and Reporting Period
Company: Revelation Biosciences, Inc. (REVB)
Filing Type: Form 8-K (Current Report)
Date of Report: August 01, 2024
Reporting Period: Specific event date (August 1, 2024)
Key Financial Metrics
This filing does not report standard periodic financial metrics such as revenue, profit, cash flow, or operating margins. The primary financial data point disclosed is a legal judgment:
- Legal Judgment Amount: Approximately $7.3 million (including interest).
- Liquidity Status: The Company states it has sufficient cash resources to satisfy the judgment.
Material Changes
The material change reported is the finalization of a legal dispute regarding unpaid banking and advisory fees:
- Case Background: LifeSci Capital LLC filed suit in February 2022 seeking approximately $5.3 million plus interest for fees related to the 2022 business combination with Petra Acquisition.
- Procedural History: A Magistrate Judge recommended summary judgment for LifeSci Capital LLC on December 1, 2023.
- Current Status: On August 1, 2024, the U.S. District Court for the Southern District of New York adopted the Magistrate Judge's report, granting summary judgment and issuing a final judgment of approximately $7.3 million against the Company.
Outlook, Management Commentary, and Risks
Management Commentary:
- The Company is currently in the process of satisfying the $7.3 million judgment.
- Management asserts that based on available cash, paying the judgment will not have an immediate impact on the Company's development and clinical trial programs.
- The primary risk is the immediate cash outflow required to settle the $7.3 million liability.
- The filing does not disclose any other new risks or contingencies beyond this legal resolution.
Key Facts for Investor Verification
- Verify the Company's current cash and cash equivalents balance in the most recent 10-Q or 10-K to confirm the assertion of sufficient liquidity to cover the $7.3 million judgment.
- Monitor subsequent filings for confirmation of the payment date and any potential impact on future capital raising activities.
- Review the Company's clinical trial pipeline status to ensure no delays have occurred due to the cash outflow, despite management's current assessment.